These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 7657166)

  • 1. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.
    Maheswaran S; Englert C; Bennett P; Heinrich G; Haber DA
    Genes Dev; 1995 Sep; 9(17):2143-56. PubMed ID: 7657166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional properties of WT1.
    Haber DA; Englert C; Maheswaran S
    Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells.
    Nichols KE; Re GG; Yan YX; Garvin AJ; Haber DA
    Cancer Res; 1995 Oct; 55(20):4540-3. PubMed ID: 7553624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of p21 by the Wilms' tumor suppressor gene WT1.
    Englert C; Maheswaran S; Garvin AJ; Kreidberg J; Haber DA
    Cancer Res; 1997 Apr; 57(8):1429-34. PubMed ID: 9108440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
    Mayo MW; Wang CY; Drouin SS; Madrid LV; Marshall AF; Reed JC; Weissman BE; Baldwin AS
    EMBO J; 1999 Jul; 18(14):3990-4003. PubMed ID: 10406804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells.
    Maheswaran S; Englert C; Lee SB; Ezzel RM; Settleman J; Haber DA
    Oncogene; 1998 Apr; 16(16):2041-50. PubMed ID: 9572485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter.
    Webster NJ; Kong Y; Sharma P; Haas M; Sukumar S; Seely BL
    Biochem Mol Med; 1997 Dec; 62(2):139-50. PubMed ID: 9441865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical and functional interaction between WT1 and p53 proteins.
    Maheswaran S; Park S; Bernard A; Morris JF; Rauscher FJ; Hill DE; Haber DA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5100-4. PubMed ID: 8389468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of insulin-like growth factor I receptor gene expression by the Wilms' tumor suppressor WT1.
    Werner H; Roberts CT; Rauscher FJ; LeRoith D
    J Mol Neurosci; 1996; 7(2):111-23. PubMed ID: 8873895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
    Zhang X; Xing G; Saunders GF
    Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53.
    Stanhope-Baker P; Kessler PM; Li W; Agarwal ML; Williams BR
    J Biol Chem; 2004 Aug; 279(32):33575-85. PubMed ID: 15155752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.
    Englert C; Hou X; Maheswaran S; Bennett P; Ngwu C; Re GG; Garvin AJ; Rosner MR; Haber DA
    EMBO J; 1995 Oct; 14(19):4662-75. PubMed ID: 7588596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Wilms' tumor suppressor gene (wt1) product represses different functional classes of transcriptional activation domains.
    Lee TH; Moffett P; Pelletier J
    Nucleic Acids Res; 1999 Jul; 27(14):2889-97. PubMed ID: 10390530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional repression of human insulin-like growth factor-II P4 promoter by Wilms' tumor suppressor WT1.
    Lee YI; Kim SJ
    DNA Cell Biol; 1996 Feb; 15(2):99-104. PubMed ID: 8634146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAX 8 regulates human WT1 transcription through a novel DNA binding site.
    Fraizer GC; Shimamura R; Zhang X; Saunders GF
    J Biol Chem; 1997 Dec; 272(49):30678-87. PubMed ID: 9388203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms' tumour-suppressor protein isoforms have opposite effects on Igf2 expression in primary embryonic cells, independently of p53 genotype.
    Duarte A; Caricasole A; Graham CF; Ward A
    Br J Cancer; 1998; 77(2):253-9. PubMed ID: 9460996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
    McCoy C; McGee SB; Cornwell MM
    Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
    Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
    Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
    Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
    Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.